Liver Disease Clinical Trials in Los Angeles

Showing 1-20 of 42 trials

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

NCT02968810

This phase II trial studies how well simvastatin works in preventing liver cancer in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

CirrhosisHepatocellular Carcinoma

National Cancer Institute (NCI)52 participantsStarted Jun 2017

Los Angeles, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +2 more locations

COMPLETEDNA< 1 mile

GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery

NCT05900037

This is a pre-market, prospective, randomized (1:1), multicenter, pivotal clinical investigation. The purpose of this investigation is to determine the clinical performance of GATT-Patch as compared with SURGICEL® Original for the management of minimal, mild, or moderate bleeding during minimally invasive liver and gallbladder surgery.

Intraoperative BleedingLiver DiseasesGallbladder Diseases+1 more

GATT Technologies BV53 participantsStarted Oct 2023

Los Angeles, California, United States • St Louis, Missouri, United States • Pennington, New Jersey, United States +3 more locations

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery

Liver Disease Trials in Other Cities

Social & Contextual Impact on Children Undergoing Liver Transplantation

Liver Cirrhosis Network Cohort Study

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Longitudinal Study of Mitochondrial Hepatopathies

Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions

Phase 2b Study of GSK4532990 in Adults With NASH

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

Communication During Hospitalization About Resuscitation Trial

Other Conditions in Los Angeles